Moderna, Merck move toward filing for personalized melanoma therapy as COVID sales lift Q3
Moderna and Merck are advancing their personalized melanoma therapy, intismeran, toward regulatory approval. Moderna's Q3 earnings show a 90% revenue drop from 2022 to 2025 due to reduced COVID-19 vaccine demand. The Phase 3 trial showed a 42% reduction in recurrence or death risk when combined with Keytruda. Moderna shares have risen over 700% this year, driven by investor excitement over the cancer program.
How this was made
The 30-second read
Why it matters
The trial data provide a clear catalyst that could drive significant upside for both partners, especially Moderna.
Market read
First‑time disclosure of positive Phase 3 results for a high‑profile mRNA oncology candidate, likely to move stocks and influence the biotech sector.
What to watch
Potential competition from other personalized cancer vaccine platforms and the need for further data in other tumor types.
Background
Moderna's earnings release disclosed the upcoming filing for its personalized melanoma vaccine, marking a shift from its COVID‑19 focus to oncology.
Ticker impact
Moderna announced Phase 3 trial results for its personalized melanoma vaccine intismeran, showing a 42% reduction in recurrence risk.
upward pressure as market prices in the efficacy data and upcoming filing prospects
Phase 3 results are a material catalyst for a large biotech; the data are strong and first disclosed.
Merck co‑developed the intismeran melanoma vaccine with Moderna and paid $250 million to jointly commercialize the therapy.
slight upward pressure as investors value Merck's share of future profits
Merck benefits from the partnership but the catalyst is less direct than for Moderna.
Market effects
Strengthens the mRNA oncology pipeline, may boost investor interest in biotech and personalized cancer vaccines.
Positive for US biotech sector; limited regional effect.
Highlights the potential of mRNA therapeutics beyond infectious disease, relevant to global pharma investors.
Counterpoint
Skeptics may question long‑term durability of benefit and regulatory hurdles, suggesting caution.
Key entities
- companyModerna
US‑listed biotech developing mRNA‑based personalized cancer vaccines.
- companyMerck
US‑listed pharma partner co‑developing the melanoma vaccine.
